SOPHiA GENETICS (NASDAQ:SOPH) CEO Jurgi Camblong Sells 4,486 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 4,486 shares of the business’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $4.77, for a total value of $21,398.22. Following the completion of the transaction, the chief executive officer directly owned 3,302,839 shares of the company’s stock, valued at approximately $15,754,542.03. This trade represents a 0.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

SOPHiA GENETICS Trading Up 2.1%

Shares of SOPHiA GENETICS stock opened at $4.96 on Friday. The company has a market capitalization of $339.71 million, a price-to-earnings ratio of -9.73 and a beta of 1.13. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. SOPHiA GENETICS SA has a 12-month low of $2.58 and a 12-month high of $5.70. The firm’s 50-day moving average price is $4.87 and its two-hundred day moving average price is $4.53.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The firm had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. On average, analysts forecast that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Institutional investors have recently added to or reduced their stakes in the stock. Green Alpha Advisors LLC boosted its position in SOPHiA GENETICS by 10.8% in the fourth quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock valued at $213,000 after buying an additional 4,444 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after buying an additional 6,205 shares during the last quarter. Savvy Advisors Inc. acquired a new position in shares of SOPHiA GENETICS during the third quarter worth $48,000. Squarepoint Ops LLC acquired a new position in shares of SOPHiA GENETICS during the third quarter worth $49,000. Finally, Perkins Capital Management Inc. bought a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $49,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have weighed in on SOPH. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. BTIG Research reissued a “buy” rating and set a $7.00 price target on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Finally, Guggenheim upped their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.